Longboard Pharmaceuticals, Inc. announced the initiation of a Phase 1 randomized, double-blind, placebo-controlled, SAD clinical study of LP659. LP659 is an oral, centrally acting, next-generation sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator in development for the potential treatment of rare neuroinflammatory conditions. The primary objective of this Phase 1 randomized, double-blind, placebo-controlled, single-ascending dose clinical study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of LP659 in up to 48 healthy adult volunteers.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
31.58 USD | -9.44% |
|
+2.13% | +423.71% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+423.71% | 1.23B | |
+18.43% | 124B | |
+19.81% | 114B | |
+19.62% | 25.83B | |
-23.74% | 19.42B | |
-18.17% | 16.2B | |
-19.97% | 15.31B | |
+57.08% | 14.32B | |
+7.95% | 14.31B | |
-49.33% | 14.19B |
- Stock Market
- Equities
- LBPH Stock
- News Longboard Pharmaceuticals, Inc.
- Longboard Pharmaceuticals Announces Initiation of First-In-Human Phase 1 Clinical Study of Lp659 in Adult Healthy Volunteers